Qian JM, Martin AM, Martin K, et al. - For the management of brain metastases (BrM), synergy between immune checkpoint therapy (ICT) and radiotherapy (RT) has been suggested in prior literature, so researchers investigated the optimal timing of therapy to maximize this synergy. Participants were 199 patients with melanoma and non–small cell lung cancer with BrM who were treated with ICT and RT between 2007 and 2016. Authors included individual metastases only if they were managed with RT within 90 days of ICT, and this was done to attenuate selection biases. The definition of concurrent treatment was RT delivered on the same day as or in between doses of an ICT course. The researchers considered all other treatment as nonconcurrent. According to the findings, improved response rates and reduction in local recurrence of brain metastases may be afforded by concurrent RT and ICT vs treatment that was nonconcurrent but delivered within 90 days.